Latest news with #InvestmentPartners
Globe and Mail
5 days ago
- Business
- Globe and Mail
GlucoGuard Receives $43 Million Enterprise Valuation Research Report
Del Mar, California--(Newsfile Corp. - June 10, 2025) - Harbinger Research, LLC an independent equity research firm with a focus on the small cap and microcap stocks, announced today that it has published a new research report on American Diversified Holdings Corporation/GlucoGuard (OTC Pink: ADHC). The report includes a valuation analysis, multi-year financial forecast model, and a value estimate of the Company and its shares. The report puts a fully diluted price target of .0012 equivalent to a $43 million enterprise valuation, assuming full dilution for required developmental capital at the current stock price. As the stock price increases, the dilution would decline accordingly raising the price target. Currently, ADHC is working with Investment Partners on Capital Formation that will benefit the enterprise valuation model utilizing non-dilutive or controlled dilutive financial models. As the development process continues further Intellectual Property filings with the USPTO is anticipated further enhancing GlucoGuards' valuation proposition. A main catalyst for GlucoGuards valuation will be fully described in future releases with a full analysis of the artificial intelligence and predictive learning aspect of the Bio Tracking and recording of blood Glucose levels. To access the research report, please visit the Harbinger Research website at: 2023-06-02 American Diversified Holdings Corp. Coverage Initiation Report ( "Management views the $43 M enterprise value to be conservative due to ability of the GlucoGuard technology to meet the unmet need of hypoglycemia and the severe problems of "Death in Bed"," commented ADHC. "Additionally, this report does not incorporate GlucoGuards' AI and Predictive learning software components and related IP due to its developing nature," concluded ADHC. Key Aspects of the Report 537mm Diabetic Patients Worldwide. 37 mm Diabetic Patients In the US. 3.7 Type 1 Diabetics in the US. 190k to 380K Potential Patients in the US. a potential market of $360 MM to $720MM in revenues. IN ADDITIONAL NEWS ADHC is in negotiations for a strategic partnership to license the GlucoGuard Technology to the Eurpean Union for upfront cash payments, milestone cash payments and cash payment royalties from revenues. Arete Biosciences development contract has been initially funded and is expected to expand into patient studies. ADHC 6-15-25 Quartely disclosure filing is expected to be filed this week ahead of the deadline. Dexcom APP integration and AI software system is under review and should be proceeding to the next phase in the near term. Patent Counsel is updating GlucoGuards' IP with the USPTO. Shareholders should anticipate and continual stream of announcements on these developments and more in the near future. About Harbinger Research, LLC Harbinger Research, LLC is one of a new breed of issuer-sponsored research boutiques, providing unbiased equity research coverage to smaller issuers that cannot attract research coverage from traditional brokerage firm's research departments. Our mission is to help both investors and public issuers by improving the availability of issuer information and by providing sound, unbiased analysis of our issuer clients' businesses, industries, and current market valuation. The policies of Harbinger Research, LLC require that all personnel strictly adhere to the CFA Institute's Code of Ethics and Standards of Professional Conduct, and its Best Practice Guidelines Governing Analyst / Corporate Issuer Relations. Please see for more information. To view our disclosures and disclaimers, or for more information, visit Harbinger Research, LLC Brian Connell, CFA Senior Research Analyst brian@ GlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. To view an enhanced version of this graphic, please visit: To view an enhanced version of this graphic, please visit: ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION John Cacchioli, CEO American Diversified Holdings Corporation Telephone: (212) 537-5900 INVESTOR HOTLINE 858-325-7098 Email: JC@ ADHCInvestor@ SOCIAL MEDIA TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
Yahoo
06-04-2025
- Business
- Yahoo
Is Mission Produce (AVO) A Small Cap Stock with Huge Upside Potential?
We recently published a list of . In this article, we are going to take a look at where Mission Produce, Inc. (NASDAQ:AVO) stands against other small cap stocks with huge upside potential. In times when everyone is chasing high-cap powerhouses, knowing the right stock to invest in at the right time and the right price is highly essential. In this race for Wall Street giants, one must slow down and ask if the stock is really worth it. Or better – is it set to yield the same returns as a high-growth small-cap stock? As Francis Gannon, Co-Chief Investment Officer at Royce Investment Partners, says: 'Small-cap stocks are a 'forgotten' group that present lucrative opportunities for investors seeking diversification amid market uncertainties.' Small-cap stocks have a market capitalization between $300 million and $2 billion. Although generally more volatile and risky, history shows that small-cap stocks have often outperformed large-cap stocks. During the tech bubble of the 1990s, large-cap stocks were everyone's favorite, until the bubble burst in March 2000, when more and more small-cap companies witnessed better performance. In general, the performance of the stock doesn't entirely depend on whether the stock is large-cap or small-cap but more on where the macro and micro environments are taking the business. However, since the small-cap stocks are usually away from the analysts' eyes, they are more undervalued, and so can provide a solid return on the investment. Since there is a high growth potential for such a stock, small-cap stocks are highly valued by analysts. As the business itself is in an early stage of growth, there is more room for a stock boom. Volatility is another reason for holding these stocks. There is an increased likelihood of short-term trading and price swings that an investor can capitalize on. Additionally, many such stocks operate in specialized or niche markets, allowing the analysts to leverage interesting and unique business models, and that too, if successful, can return immensely. The fact that small-cap stocks are common targets for mergers and acquisitions is another reason to believe in these stocks. Analysts keep track of these stocks with the expectation of buyouts, which often leads to a premium in share price. A research report by John Hancock Investment Management on understanding the performance of small-cap stocks indicated that, historically, small-cap stocks have had higher average returns than large-cap stocks. As small-cap stocks work well in diversified portfolios, they behave differently than large-cap stocks. The study examined the existence of size premiums in the United States, emphasizing the historical performance of Fama/French U.S. Small and Large Cap portfolios. The findings show that since the 1920s, small-cap stocks have outperformed large-cap stocks. Another research by Invesco in 2020 revealed that small caps have outpaced large caps from the past four recessions in all but one of the following 1- and 3-year periods. To decide which small-cap stock is right for you, it is pertinent to monitor closely not only the stock itself but also its peers, as it provides a bigger picture. The factors that are crucial in the choice you make include the liquidity position, sensitivity to market swings, financial stability, and connection to AI. The stocks that we have selected are among the ones yielding high upside potential across a range of industries like financial, food, and mining. We have used Finviz and Stock Analysis screeners to select ten stocks with market capitalizations between $300 million and $2 billion. The one-year price targets have been extracted from Yahoo Finance to calculate the upside potential based on the stocks' prices as of March 28, 2025. These companies are then listed according to their upside potential. At Insider Monkey, we are obsessed with hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Aerial view of a large warehouse loaded with pallets and crates of food products. Upside Potential: 68% Market Capitalization: $719.247 million Mission Produce, Inc. (NASDAQ:AVO) is a global producer and distributor of avocados, mangoes, and blueberries. Founded in 1983, the company owns and operates four packaging facilities in major growing locations worldwide, including California, Mexico, and Peru. With three main segments- Marketing and Distribution, International Farming, and Blueberries- the company offers ripening, custom packaging, logistical management, and quality assurance services. By promoting ethical supply chains, the company aims to cultivate a better future for upcoming generations. While some stocks have short-term gains and others return in the long term, Mission Produce, Inc. (NASDAQ:AVO) is an all-rounder stock. The global and United States demand for avocados has been on the rise for years, owing to the demographic boom and the superfood taking over the food trends. With people switching to healthier food choices and the popularity of avocados among today's generation, the stock is more and more compelling with each passing day. In the past, while we have seen avocados be the growth catalyst for Mission Produce, Inc. (NASDAQ:AVO), the recent trend shows that the mango segment is not slowing as well. If we consider the avocado business on its own, rising prices due to the demand surge and population rise are just adequate for the company's decent profit margins. Amid rising commercial tensions between Mexico and the U.S., the global sourcing capabilities of Mission Produce, Inc. (NASDAQ:AVO) make it a valued player and stock to not only benefit from the trade war, with prices going up, but also avoid tariffs by supplying to non-trade war countries. The company's plans to expand by investing in Guatemala's avocado facilities and Peru's blueberry farming mean that Mission Produce, Inc. (NASDAQ:AVO) is ready to step up the game. In this globalized world, mango is following in the footsteps of avocados, particularly in the U.S., and before we know it, mango will be the next avocado for the company. AVO is one of the best stocks with the biggest upside. Overall, AVO ranks 10th on our list of small cap stocks with huge upside potential. While we acknowledge the potential of AVO, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than AVO but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
